ePrints

Recent advances in CDK inhibitors for cancer therapy

Lookup NU author(s): Amy Heptinstall, Dr Celine CanoORCiD, Dr Ian HardcastleORCiD

Downloads

• Accepted version [.pdf]

Licence

This is the authors' accepted manuscript of a review published in its final definitive form in 2018. For re-use rights please refer to the publishers terms and conditions.

Abstract

Inhibition of cyclin-dependent kinases is an attractive approach to cancer therapy due to their vital role in cell growth and transcription. Pan-CDK inhibitors have shown some clinical benefit, and trials are ongoing. Selective CDK4 and CDK6 inhibitors have been licenced for the treatment of hormone responsive, RB positive breast cancer in combination with anti-hormonal agents. Selective inhibitors of CDKs 7, 8, 9 and 12 have been identified across a range of chemotypes.

Publication metadata

Author(s): Heptinstall AB, Adiyasa IWS, Cano C, Hardcastle IR

Publication type: Review

Publication status: Published

Journal: Future Medicinal Chemistry

Year: 2018

Volume: 10

Issue: 11

Pages: 1369–1388

Print publication date: 01/06/2018

Online publication date: 30/05/2018

Acceptance date: 19/03/2018

ISSN (print): 1756-8919

ISSN (electronic): 1756-8927

URL: https://doi.org/10.4155/fmc-2017-0246

DOI: 10.4155/fmc-2017-0246

Share